Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,809 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A

NCT00858897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cysteine isotope infusion at normoglycemia vs hyperglycemia, Regular Insulin
Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 20, 2026, 10:13 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment

NCT01099618
View directory record Official record
Conditions
Ketosis Prone Diabetes, Diabetes Ketoacidosis, Hyperglycemia
Interventions
metformin, placebo, Sitagliptin
Drug
Lead sponsor
Dawn Smiley MD
Other
Eligibility
19 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

NCT02299050
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cycloset
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 69 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED

NCT06899191
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Hyperglycemia, Insulin Dependent Diabetes
Interventions
Hemoglobin A1c, Observation Unit
Diagnostic Test · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Terminated Phase 1 Interventional

Trial of New Dietary Treatment of Diabetes

NCT00128089
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dietary treatment
Behavioral
Lead sponsor
Manassas Internal Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2005 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents

NCT00097071
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 18 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

NCT00417989
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 70 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Boulder, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes

NCT00645840
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anakinra
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403

NCT01131091
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SK-0403
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study

NCT02877680
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
T1Doing Well
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 20, 2026, 10:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

NCT01515384
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
18F-AV-133
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes

NCT02206152
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Results available

Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

NCT02328040
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo and Insulin monotherapy via CL, Sitagliptin and insulin/novolog via CL
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
14 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 4 Interventional

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

NCT05757713
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
teplizumab
Biological
Lead sponsor
Sanofi
Industry
Eligibility
0 Years to 7 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Active, not recruiting Not applicable Interventional

Multi-Site Eating Disorder Prevention Program for Type 1 Diabetes

NCT05399446
View directory record Official record
Conditions
Type 1 Diabetes, Eating Disorders
Interventions
Diabetes Body Project, Educational Group
Behavioral
Lead sponsor
Oslo University Hospital
Other
Eligibility
14 Years to 35 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

NCT01336023
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
146
States / cities
Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Insulet Artificial Pancreas Free-Living IDE3

NCT03216460
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Insulet automated glucose control system
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
2 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Palo Alto, California • Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 20, 2026, 10:13 PM EDT
Recruiting No phase listed Observational

Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes

NCT07650682
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Dependent Diabetes
Interventions
Not listed
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Transition of Diabetes Care From Pediatric to Adult Healthcare Providers.

NCT03844126
View directory record Official record
Conditions
Transition
Interventions
Transition classes
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
16 Years to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 20, 2026, 10:13 PM EDT
Recruiting No phase listed Observational

A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

NCT07260110
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

NCT03347968
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MEDI0382, Warfarin, Esmolol
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 20, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes

NCT04878120
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Standard HCL System, HCL System with Smart Bolus Calculator
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 20, 2026, 10:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Children With Diabetes at Risk for Heart Disease.

NCT02275091
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
12 Years to 21 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 20, 2026, 10:13 PM EDT